| 1 | Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers | 6.8 | 11 | Citations (PDF) |
| 2 | PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair | 5.2 | 25 | Citations (PDF) |
| 3 | H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours | 11.0 | 46 | Citations (PDF) |
| 4 | Rat Models of Hormone Receptor-Positive Breast Cancer | 1.6 | 23 | Citations (PDF) |
| 5 | Transcriptomic Analysis of Pubertal and Adult Virgin Mouse Mammary Epithelial and Stromal Cell Populations | 1.6 | 7 | Citations (PDF) |
| 6 | Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts | 3.2 | 6 | Citations (PDF) |
| 7 | Mechanisms that clear mutations drive field cancerization in mammary tissue | 31.3 | 32 | Citations (PDF) |
| 8 | CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer | 11.0 | 102 | Citations (PDF) |
| 9 | Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers | 11.0 | 42 | Citations (PDF) |
| 10 | Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors | 4.4 | 41 | Citations (PDF) |
| 11 | FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks | 8.2 | 20 | Citations (PDF) |
| 12 | A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression | 28.7 | 27 | Citations (PDF) |
| 13 | Imagine beyond: recent breakthroughs and next challenges in mammary gland biology and breast cancer research | 1.6 | 6 | Citations (PDF) |
| 14 | Mouse intraductal modeling of primary ductal carcinoma in situ | 0.8 | 2 | Citations (PDF) |
| 15 | MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer | 5.9 | 23 | Citations (PDF) |
| 16 | Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity | 4.7 | 26 | Citations (PDF) |
| 17 | Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids | 0.8 | 1 | Citations (PDF) |
| 18 | A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture | 4.2 | 52 | Citations (PDF) |
| 19 | Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer | 3.4 | 15 | Citations (PDF) |
| 20 | Epithelial-to-Mesenchymal Transition Drives Invasiveness of Breast Cancer Brain Metastases | 2.7 | 16 | Citations (PDF) |
| 21 | Truncated FGFR2 is a clinically actionable oncogene in multiple cancers | 31.3 | 100 | Citations (PDF) |
| 22 | Learning to distinguish progressive and non-progressive ductal carcinoma in situ | 33.8 | 49 | Citations (PDF) |
| 23 | MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling | 11.0 | 146 | Citations (PDF) |
| 24 | Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts | 14.1 | 179 | Citations (PDF) |
| 25 | The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice | 2.4 | 20 | Citations (PDF) |
| 26 | Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum | 2.7 | 8 | Citations (PDF) |
| 27 | SMARCAD1-mediated active replication fork stability maintains genome integrity | 8.2 | 36 | Citations (PDF) |
| 28 | PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair | 2.7 | 11 | Citations (PDF) |
| 29 | Understanding and overcoming resistance to PARP inhibitors in cancer therapy | 53.1 | 488 | Citations (PDF) |
| 30 | Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer | 11.0 | 83 | Citations (PDF) |
| 31 | Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency | 8.7 | 303 | Citations (PDF) |
| 32 | A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair | 4.2 | 18 | Citations (PDF) |
| 33 | Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate | 3.5 | 17 | Citations (PDF) |
| 34 | Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions | 2.7 | 49 | Citations (PDF) |
| 35 | Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps | 8.7 | 93 | Citations (PDF) |
| 36 | TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development | 2.9 | 64 | Citations (PDF) |
| 37 | Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining | 4.4 | 53 | Citations (PDF) |
| 38 | Functional Categorization of
BRCA1
Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays | 4.5 | 40 | Citations (PDF) |
| 39 | Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms | 4.2 | 9 | Citations (PDF) |
| 40 | BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers | 8.7 | 137 | Citations (PDF) |
| 41 | In situ
CRISPR‐Cas9 base editing for the development of genetically engineered mouse models of breast cancer | 5.2 | 59 | Citations (PDF) |
| 42 | Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin | 11.0 | 36 | Citations (PDF) |
| 43 | Ductal carcinoma in situ: to treat or not to treat, that is the question | 4.2 | 285 | Citations (PDF) |
| 44 | Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis | 31.3 | 475 | Citations (PDF) |
| 45 | Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer | 11.0 | 76 | Citations (PDF) |
| 46 | GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice | 1.6 | 4 | Citations (PDF) |
| 47 | PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer | 6.8 | 688 | Citations (PDF) |
| 48 | EZH2 Is Overexpressed in
BRCA1
-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy | 4.5 | 43 | Citations (PDF) |
| 49 | Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response | 12.8 | 169 | Citations (PDF) |
| 50 | Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice | 1.6 | 3 | Citations (PDF) |
| 51 | Long‐term expanding human airway organoids for disease modeling | 5.2 | 1,023 | Citations (PDF) |
| 52 | Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer | 2.7 | 62 | Citations (PDF) |
| 53 | Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas | 4.4 | 68 | Citations (PDF) |
| 54 | RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer | 8.1 | 424 | Citations (PDF) |
| 55 | Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance | 5.2 | 9 | Citations (PDF) |
| 56 | E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer | 6.8 | 122 | Citations (PDF) |
| 57 | Easy quantification of template-directed CRISPR/Cas9 editing | 11.2 | 199 | Citations (PDF) |
| 58 | Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment | 6.8 | 201 | Citations (PDF) |
| 59 | The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity | 11.0 | 101 | Citations (PDF) |
| 60 | The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells | 4.4 | 156 | Citations (PDF) |
| 61 | αE‐catenin is a candidate tumor suppressor for the development of E‐cadherin‐expressing lobular‐type breast cancer | 3.2 | 48 | Citations (PDF) |
| 62 | The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations | 28.7 | 180 | Citations (PDF) |
| 63 | The shieldin complex mediates 53BP1-dependent DNA repair | 31.3 | 649 | Citations (PDF) |
| 64 | Haploid genetic screens identify genetic vulnerabilities to microtubule‐targeting agents | 2.8 | 16 | Citations (PDF) |
| 65 | Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division | 4.2 | 46 | Citations (PDF) |
| 66 | Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547 | 4.2 | 41 | Citations (PDF) |
| 67 | Mouse models in the era of large human tumour sequencing studies | 1.8 | 12 | Citations (PDF) |
| 68 | BRCA1‐associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling | 3.2 | 12 | Citations (PDF) |
| 69 | Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality | 28.7 | 344 | Citations (PDF) |
| 70 | Interrogating open issues in cancer precision medicine with patient-derived xenografts | 33.8 | 650 | Citations (PDF) |
| 71 | Genetically engineered mouse models in oncology research and cancer medicine | 4.7 | 487 | Citations (PDF) |
| 72 | Identifying transposon insertions and their effects from RNA-sequencing data | 11.2 | 11 | Citations (PDF) |
| 73 | Prophylactic window therapy with the clinical poly(ADP‐ribose) polymerase inhibitor olaparib delays BRCA1‐deficient mammary tumour formation in mice | 3.2 | 4 | Citations (PDF) |
| 74 | PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models | 4.2 | 128 | Citations (PDF) |
| 75 | EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation | 12.8 | 333 | Citations (PDF) |
| 76 | Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice | 4.5 | 31 | Citations (PDF) |
| 77 | BRCA
1 and
BRCA
2 tumor suppressors protect against endogenous acetaldehyde toxicity | 4.7 | 72 | Citations (PDF) |
| 78 | Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells | 11.0 | 108 | Citations (PDF) |
| 79 | Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma | 14.1 | 72 | Citations (PDF) |
| 80 | Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β | 1.9 | 34 | Citations (PDF) |
| 81 | BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance | 13.6 | 151 | Citations (PDF) |
| 82 | Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer | 3.4 | 202 | Citations (PDF) |
| 83 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences | 31.3 | 2,179 | Citations (PDF) |
| 84 | The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin | 4.2 | 277 | Citations (PDF) |
| 85 | The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models | 4.2 | 91 | Citations (PDF) |
| 86 | PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma | 4.4 | 53 | Citations (PDF) |
| 87 | Replication fork stability confers chemoresistance in BRCA-deficient cells | 31.3 | 909 | Citations (PDF) |
| 88 | p120-Catenin Is Critical for the Development of Invasive Lobular Carcinoma in Mice | 1.6 | 14 | Citations (PDF) |
| 89 | Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours | 12.8 | 90 | Citations (PDF) |
| 90 | Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer | 1.6 | 12 | Citations (PDF) |
| 91 | Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland | 2.9 | 134 | Citations (PDF) |
| 92 | HELB Is a Feedback Inhibitor of DNA End Resection | 8.7 | 149 | Citations (PDF) |
| 93 | Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors | 4.5 | 50 | Citations (PDF) |
| 94 | BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1 | 6.8 | 135 | Citations (PDF) |
| 95 | Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation | 2.8 | 73 | Citations (PDF) |
| 96 | Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase | 3.2 | 10 | Citations (PDF) |
| 97 | Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2+ breast cancerPain, 2015, 156, 1424-1432 | 2.9 | 45 | Citations (PDF) |
| 98 | Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells | 1.5 | 132 | Citations (PDF) |
| 99 | Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression | 4.4 | 84 | Citations (PDF) |
| 100 | The Use of Mass Spectrometry Imaging to Predict Treatment Response of Patient-Derived Xenograft Models of Triple-Negative Breast Cancer | 2.3 | 28 | Citations (PDF) |
| 101 | BRCA
1 and Ct
IP
promote alternative non‐homologous end‐joining at uncapped telomeres | 5.2 | 31 | Citations (PDF) |
| 102 | BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance | 4.2 | 68 | Citations (PDF) |
| 103 | Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model | 8.1 | 110 | Citations (PDF) |
| 104 | Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer | 5.3 | 123 | Citations (PDF) |
| 105 | CopywriteR: DNA copy number detection from off-target sequence data | 12.1 | 214 | Citations (PDF) |
| 106 | REV7 counteracts DNA double-strand break resection and affects PARP inhibition | 31.3 | 589 | Citations (PDF) |
| 107 | IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis | 31.3 | 1,697 | Citations (PDF) |
| 108 | Lack of Genomic Heterogeneity at High-Resolution aCGH between Primary Breast Cancers and Their Paired Lymph Node Metastases | 1.5 | 9 | Citations (PDF) |
| 109 | The Interface Between Cancer Numerical and Structural Chromosomal Instability: Mechanisms Accelerating Cancer Diversity | 8.1 | 0 | Citations (PDF) |
| 110 | Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors? | 4.5 | 155 | Citations (PDF) |
| 111 | Rapid target gene validation in complex cancer mouse models using re‐derived embryonic stem cells | 4.7 | 90 | Citations (PDF) |
| 112 | Chromosome instability induced by Mps1 and p53 mutation generates aggressive lymphomas exhibiting aneuploidy-induced stress | 5.3 | 104 | Citations (PDF) |
| 113 | Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways | 23.8 | 776 | Citations (PDF) |
| 114 | Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research | 6.8 | 1,675 | Citations (PDF) |
| 115 | Functional
Ex Vivo
Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment | 4.5 | 164 | Citations (PDF) |
| 116 | Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping | 20.2 | 284 | Citations (PDF) |
| 117 | Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy | 3.4 | 102 | Citations (PDF) |
| 118 | Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance | 2.7 | 24 | Citations (PDF) |
| 119 | Genetically engineered mouse models of PI3K signaling in breast cancer | 2.8 | 35 | Citations (PDF) |
| 120 | ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets | 11.0 | 40 | Citations (PDF) |
| 121 | BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny | 2.9 | 36 | Citations (PDF) |
| 122 | A Preclinical Mouse Model of Invasive Lobular Breast Cancer Metastasis | 4.2 | 65 | Citations (PDF) |
| 123 | An α‐E‐catenin (CTNNA1) mutation in hereditary diffuse gastric cancer | 3.2 | 212 | Citations (PDF) |
| 124 | Somatic loss of p53 leads to stem/progenitor cell amplification in both mammary epithelial compartments, basal and luminal | 2.7 | 35 | Citations (PDF) |
| 125 | Loss of 53BP1 Causes PARP Inhibitor Resistance in
Brca1
-Mutated Mouse Mammary Tumors | 6.8 | 516 | Citations (PDF) |
| 126 | A High-Throughput Functional Complementation Assay for Classification of
BRCA1
Missense Variants | 6.8 | 126 | Citations (PDF) |
| 127 | Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling | 4.2 | 52 | Citations (PDF) |
| 128 | Proteomics of Genetically Engineered Mouse Mammary Tumors Identifies Fatty Acid Metabolism Members as Potential Predictive Markers for Cisplatin Resistance | 3.5 | 27 | Citations (PDF) |
| 129 | BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival | 5.9 | 279 | Citations (PDF) |
| 130 | Palb2
synergizes with
Trp53
to suppress mammary tumor formation in a model of inherited breast cancer | 5.3 | 57 | Citations (PDF) |
| 131 | Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool | 2.7 | 47 | Citations (PDF) |
| 132 | Analysis of Tumor Heterogeneity and Cancer Gene Networks Using Deep Sequencing of MMTV-Induced Mouse Mammary Tumors | 1.5 | 41 | Citations (PDF) |
| 133 | Epidermal Snail expression drives skin cancer initiation and progression through enhanced cytoprotection, epidermal stem/progenitor cell expansion and enhanced metastatic potential | 7.7 | 55 | Citations (PDF) |
| 134 | Use of a Single Hybrid Imaging Agent for Integration of Target Validation with In Vivo and Ex Vivo Imaging of Mouse Tumor Lesions Resembling Human DCIS | 1.5 | 24 | Citations (PDF) |
| 135 | Abstract A52: Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling 2013, , | | 0 | Citations (PDF) |
| 136 | Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol | 1.2 | 12 | Citations (PDF) |
| 137 | Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours | 31.3 | 87 | Citations (PDF) |
| 138 | Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors | 4.2 | 52 | Citations (PDF) |
| 139 | Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer | 10.4 | 123 | Citations (PDF) |
| 140 | Developmental stage‐specific contribution of LGR5+ cells to basal and luminal epithelial lineages in the postnatal mammary gland | 3.2 | 150 | Citations (PDF) |
| 141 | Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches | 2.4 | 27 | Citations (PDF) |
| 142 | The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance | 33.8 | 589 | Citations (PDF) |
| 143 | Proteomics of Mouse BRCA1-deficient Mammary Tumors Identifies DNA Repair Proteins with Potential Diagnostic and Prognostic Value in Human Breast Cancer | 3.5 | 24 | Citations (PDF) |
| 144 | Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system | 22.8 | 107 | Citations (PDF) |
| 145 | EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors | 1.5 | 26 | Citations (PDF) |
| 146 | BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance | 28.7 | 259 | Citations (PDF) |
| 147 | Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer | 1.6 | 20 | Citations (PDF) |
| 148 | Development of metastatic HER2+ breast cancer is independent of the adaptive immune system | 3.2 | 22 | Citations (PDF) |
| 149 | Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression | 3.2 | 42 | Citations (PDF) |
| 150 | Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models | 1.7 | 38 | Citations (PDF) |
| 151 | High-throughput semiquantitative analysis of insertional mutations in heterogeneous tumors | 3.2 | 40 | Citations (PDF) |
| 152 | Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice | 1.3 | 127 | Citations (PDF) |
| 153 | Computational identification of insertional mutagenesis targets for cancer gene discovery | 11.2 | 27 | Citations (PDF) |
| 154 | Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers | 3.5 | 62 | Citations (PDF) |
| 155 | Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance | 6.8 | 132 | Citations (PDF) |
| 156 | Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers | 2.1 | 40 | Citations (PDF) |
| 157 | BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations | 2.1 | 56 | Citations (PDF) |
| 158 | KC-SMARTR: An R package for detection of statistically significant aberrations in multi-experiment aCGH data | 0.9 | 22 | Citations (PDF) |
| 159 | Potential value of color-coded dynamic breast-specific gamma-imaging; comparing 99mTc-(V)-DMSA, 99mTc-MIBI, and 99mTc-HDP in a mouse mammary tumor model | 1.4 | 6 | Citations (PDF) |
| 160 | A tissue reconstitution model to study cancer cell‐intrinsic and ‐extrinsic factors in mammary tumourigenesis | 3.2 | 14 | Citations (PDF) |
| 161 | 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers | 5.9 | 951 | Citations (PDF) |
| 162 | BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping | 5.9 | 152 | Citations (PDF) |
| 163 | BRD7 is a candidate tumour suppressor gene required for p53 function | 12.8 | 201 | Citations (PDF) |
| 164 | Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan | 4.2 | 83 | Citations (PDF) |
| 165 | A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors | 4.5 | 82 | Citations (PDF) |
| 166 | Insertional Mutagenesis in Mice Deficient for
p15Ink4b, p16Ink4a, p21Cip1
, and
p27Kip1
Reveals Cancer Gene Interactions and Correlations with Tumor Phenotypes | 4.2 | 32 | Citations (PDF) |
| 167 | Identification of Networks of Co-Occurring, Tumor-Related DNA Copy Number Changes Using a Genome-Wide Scoring Approach | 1.9 | 30 | Citations (PDF) |
| 168 | Novel Candidate Cancer Genes Identified by a Large-Scale Cross-Species Comparative Oncogenomics Approach | 4.2 | 41 | Citations (PDF) |
| 169 | A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node | 1.9 | 88 | Citations (PDF) |
| 170 | Targeting homologous recombination repair defects in cancer | 11.1 | 111 | Citations (PDF) |
| 171 | Somatic structural rearrangements in genetically engineered mouse mammary tumors | 4.8 | 26 | Citations (PDF) |
| 172 | Preclinical mouse models for BRCA1-associated breast cancer | 4.2 | 46 | Citations (PDF) |
| 173 | Error-prone translesion replication of damaged DNA suppresses skin carcinogenesis by controlling inflammatory hyperplasia | 5.3 | 24 | Citations (PDF) |
| 174 | CIP2A Is Associated with Human Breast Cancer Aggressivity | 4.5 | 212 | Citations (PDF) |
| 175 | Therapeutic options for triple-negative breast cancers with defective homologous recombination | 5.8 | 29 | Citations (PDF) |
| 176 | Conditional
Pten
knock‐out mice: a model for metastatic phaeochromocytoma | 3.2 | 17 | Citations (PDF) |
| 177 | BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A | 3.4 | 103 | Citations (PDF) |
| 178 | Frat oncoproteins act at the crossroad of canonical and noncanonical Wnt-signaling pathways | 5.2 | 39 | Citations (PDF) |
| 179 | NCAM‐induced focal adhesion assembly: a functional switch upon loss of E‐cadherin | 5.2 | 177 | Citations (PDF) |
| 180 | EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer | 3.4 | 112 | Citations (PDF) |
| 181 | Modeling therapy resistance in genetically engineered mouse cancer models | 13.6 | 35 | Citations (PDF) |
| 182 | Large-Scale Mutagenesis in p19ARF- and p53-Deficient Mice Identifies Cancer Genes and Their Collaborative Networks | 23.8 | 170 | Citations (PDF) |
| 183 | Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin | 4.5 | 327 | Citations (PDF) |
| 184 | High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs | 5.3 | 953 | Citations (PDF) |
| 185 | Mouse models for BRCA1 associated tumorigenesis: From fundamental insights to preclinical utility | 2.3 | 23 | Citations (PDF) |
| 186 | How do real tumors become resistant to cisplatin? | 2.3 | 191 | Citations (PDF) |
| 187 | Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data | 11.2 | 63 | Citations (PDF) |
| 188 | What Makes Tumors Multidrug Resistant? | 2.3 | 99 | Citations (PDF) |
| 189 | Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues | 1.4 | 193 | Citations (PDF) |
| 190 | Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human
BRCA1
-mutated basal-like breast cancer | 5.3 | 481 | Citations (PDF) |
| 191 | Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer | 5.3 | 301 | Citations (PDF) |
| 192 | Aneuploidy Arises at Early Stages of Apc-Driven Intestinal Tumorigenesis and Pinpoints Conserved Chromosomal Loci of Allelic Imbalance between Mouse and Human | 2.8 | 19 | Citations (PDF) |
| 193 | Telomerase Deletion Limits Progression of p53-Mutant Hepatocellular Carcinoma With Short Telomeres in Chronic Liver Disease | 0.9 | 62 | Citations (PDF) |
| 194 | Models for angiogenesis: From fundamental mechanisms to anticancer treatment research | 1.7 | 0 | Citations (PDF) |
| 195 | MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer | 14.1 | 188 | Citations (PDF) |
| 196 | Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes | 2.1 | 69 | Citations (PDF) |
| 197 | Modeling Metastatic Breast Cancer in Mice | 1.6 | 58 | Citations (PDF) |
| 198 | Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects | 5.2 | 243 | Citations (PDF) |
| 199 | Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis | 28.7 | 553 | Citations (PDF) |
| 200 | Autotaxin, a Secreted Lysophospholipase D, Is Essential for Blood Vessel Formation during Development | 1.5 | 514 | Citations (PDF) |
| 201 | Macrophage retinoblastoma deficiency leads to enhanced atherosclerosis development in ApoE‐deficient mice | 2.3 | 30 | Citations (PDF) |
| 202 | Frat is dispensable for canonical Wnt signaling in mammals | 2.9 | 66 | Citations (PDF) |
| 203 | Mice Expressing a Mammary Gland–Specific R270H Mutation in the p53 Tumor Suppressor Gene Mimic Human Breast Cancer Development | 4.2 | 61 | Citations (PDF) |
| 204 | Human and mouse oligonucleotide-based array CGH | 11.2 | 235 | Citations (PDF) |
| 205 | A Whole-Genome Mouse BAC Microarray With 1-Mb Resolution for Analysis of DNA Copy Number Changes by Array Comparative Genomic Hybridization | 3.2 | 62 | Citations (PDF) |
| 206 | Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors | 1.5 | 304 | Citations (PDF) |
| 207 | Characterization and Functional Analysis of the Murine Frat2 Gene | 1.3 | 25 | Citations (PDF) |
| 208 | Mutagenic Insertion and Chromosome Engineering Resource (MICER) | 14.1 | 137 | Citations (PDF) |
| 209 | Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas | 5.2 | 68 | Citations (PDF) |
| 210 | Oncogene addiction | 28.7 | 74 | Citations (PDF) |
| 211 | Oncogene addictionSometimes a temporary slavery | 28.7 | 113 | Citations (PDF) |
| 212 | Conditional mouse models of sporadic cancer | 33.8 | 290 | Citations (PDF) |
| 213 | A highly efficient ligand‐regulated Cre recombinase mouse line shows that
LoxP
recombination is position dependent | 3.5 | 332 | Citations (PDF) |
| 214 | Mouse Models for Sporadic Cancer | 2.1 | 32 | Citations (PDF) |
| 215 | Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer | 14.1 | 1,018 | Citations (PDF) |
| 216 | Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells | 5.3 | 566 | Citations (PDF) |
| 217 | Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome | 3.7 | 60 | Citations (PDF) |
| 218 | Lymphoid abnormalities in CD40 ligand transgenic mice suggest the need for tight regulation in gene therapy approaches to hyper immunoglobulin M (IgM) syndrome | 3.7 | 14 | Citations (PDF) |
| 219 | Induction of medulloblastomas inp53-null mutant mice by somatic inactivation ofRbin the external granular layer cells of the cerebellum | 2.9 | 851 | Citations (PDF) |
| 220 | Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression | 5.2 | 32 | Citations (PDF) |
| 221 | In vivo analysis of Frat1 deficiency suggests compensatory activity of Frat3 | 2.6 | 38 | Citations (PDF) |
| 222 | Axin and Frat1 interact with Dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1 | 5.2 | 368 | Citations (PDF) |
| 223 | Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas | 5.2 | 121 | Citations (PDF) |
| 224 | Retroviral insertional mutagenesis as a strategy to identify cancer genes | 5.8 | 119 | Citations (PDF) |
| 225 | BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality | 2.9 | 4 | Citations (PDF) |
| 226 | NASP modulates histone turnover to drive PARP inhibitor resistance | 31.3 | 16 | Citations (PDF) |
| 227 | Chemotherapy-Treated Breast Cancer Cells Activate the WNT Signaling Pathway to Enter a Diapause-Like Early Persister State | 4.2 | 4 | Citations (PDF) |
| 228 | BRCA1 deficiency leads to aberrant epithelial differentiation in the thymus | 1.2 | 0 | Citations (PDF) |
| 229 | C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3 | 4.2 | 0 | Citations (PDF) |
| 230 | Insights from three decades of BRCA1/2 modeling in mice | 14.1 | 1 | Citations (PDF) |
| 231 | High-throughput spheroid-based assay for functional breast cancer precision medicine facilitated by deep learning | 3.6 | 1 | Citations (PDF) |
| 232 | FGFR rearrangements: oncogenic drivers and therapeutic targets | 10.6 | 0 | Citations (PDF) |
| 233 | Beyond the traditional dish: Advanced 3D ex vivo culture platforms for tumor modelling | 10.7 | 0 | Citations (PDF) |
